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The cell cycle inhibitor p15 INK4B is frequently inactivated by homozygous deletions together with p16
INK4a

/p14
ARF in many tumour types. Although it is now well established that p16
INK4a and p14 ARF act as tumour suppressor genes, the role of p15
INK4b remains to be well de®ned. In order to explore the possibility of a selective deregulation of p15
INK4b in human lung carcinogenesis, we studied p15
INK4b status in neuroendocrine (NE) lung tumours where homozygous deletions of the p16
INK4a
/p14 ARF locus are rarely observed. Expressions of p15 and p15.5 protein isoforms were analysed in a series of eight control normal lung, 12 tumour-associated normal lung, ®ve low grade and 15 high grade neuroendocrine (NE) lung tumours and relationship with a speci®c p15 INK4b methylation status was studied. Using Western blot analysis, we showed that p15 and p15.5 isoforms displayed a high heterogeneous pattern of expression in both normal and tumour tissues. P15 and p15.5 expressions were correlated in control normal lung (P50.04) whereas they were not in tumours and associated normal lung. The level of p15.5 was signi®cantly higher in associated normal lung and in tumours (P50.02 respectively), specially in low grade tumours (P50.01), than in control normal lung. Furthermore, p15.5 expression was more variable in tumours than in normal lung (P50.01) and in low grade than in high grade NE lung tumours (P50.02). Levels of p15 and p15.5 were distinct (up-or downregulated) from those observed in paired normal lung in 4/12 (33%) and 10/12 (83%) tumours respectively. Aberrant methylation at the 5' end of p15
INK4b gene was observed in 15% of NE lung tumours using PCR-based assay, in a region proximal to the translation start where methylation did not occur in control and associated normal lung. However, no correlation could be assessed with protein status. MSP analysis of CpG islands proximal to the transcription start revealed methylation in all normal and tumour samples. No correlation was found between p15
INK4b and p16 INK4a or p14 ARF status. These data suggest that complex deregulation of p15.5 is implicated in the carcinogenesis of human NE lung tumours independently of p16mRNAs, p15 and p10, both induced by TGF-b1 (Tsubari et al., 1997) . P10 is generated from an alternative splicing of p15 and is ubiquitously expressed in normal and human cell lines. Both p15 and p10 restrain cell cycle but in contrast to p15, p10 does not interact with CDK4 and CDK6 (Tsubari et al., 1997) . P15 transcript encodes two protein isoforms, p15 and p15.5, that are synthesized from two alternative, in frame, translation initiation codons (Fuxe et al., 2000) . Although structurally distinct, both proteins apparently bind to CDK4 and CDK6, inhibit DNA synthesis and can cause replicative senescence in glioma cell lines (Fuxe et al., 2000) .
It is now well established that p16 INK4a acts as a tumour suppressor gene that is inactivated by homozygous deletions, gene methylation or mutations in many tumours of diverse origin (Cairns et al., 1995; Merlo et al., 1995; Pollock et al., 1996) . In contrast, the role of p15
INK4b in human tumorigenesis remains to be well de®ned. Several observations suggest the involve-ment of p15
INK4b in the genesis/development of a number of tumours. In human carcinoma, the 9p21 chromosomic region is frequently aected by large deletions spanning in most cases both p16
INKa
/p14
ARF and p15
INK4b
loci . Although p16 INK4a is thought to be the main target for these deletions, loss of p15
has been observed with retention and expression of p16
INK4a in some cases including melanoma (Glendening et al., 1995) , brain tumours (Jen et al., 1994) and acute lymphocytic leukaemia (Rasool et al., 1995) . A selective inactivation of p15
INK4b through hypermethylation has also been reported in some glioma and in haematological malignancies (Herman et al., 1996a (Herman et al., , 1997 . Furthermore, expression of an exogenous p15
INK4b gene is able to suppress growth in recipient cells Reynisdottir et al., 1995) . Finally, Latres et al. (2000) recently showed that mice defective in p15
INK4b are prone to develop lymphoproliferative disorders and tumour formation, predominantly angiosarcoma but also lung adenocarcinoma, demonstrating that p15
INK4b is a tumour suppressor protein.
Lung tumours can be divided in non small cell lung cancer (NSCLC) and neuroendocrine (NE) lung tumours which include the very aggressive small cell lung carcinoma subtype (SCLC). Only a few studies have analysed p15
INK4b status in lung cancer. NSCLC have been principally studied. In these tumours, homozygous deletions of p15
INK4b , always together with p16
INK4a
, are frequent (Hamada et al., 1998; Xiao et al., 1995; Packenham et al., 1995) . In contrast, they are never observed in SCLC (Herman et al., 1996a; Okamoto et al., 1995; Washimi et al., 1995; Nakagawa et al., 1995; Hamada et al., 1998) . Mutations are rarely found (Rusin et al., 1996; Okamoto et al., 1995) . Methylation of the 5' end of p15
INK4b gene has been reported in a few lung cell lines (Herman et al., 1996a; Hamada et al., 1998) 
Results
Expression of p15 and p15.5 isoforms in normal lung and NE lung tumours
The status of p15 and p15.5 isoforms was studied by Western blotting in a series of eight control normal lung from patients without cancer, 12 tumourassociated normal lung taken at distance from primary tumour and 20 NE lung tumours of all histological types (Tables 1 and 2 , Figure 1 ). NE lung carcinoma consisted in ®ve low grade tumours (typical and atypical carcinoids) and 15 high grade tumours (large cell NE carcinoma and small cell lung carcinoma). Because expression of each protein was highly variable, immunoblots were analysed by densitometry and the resulting data grouped as described in Materials and methods section into the four following classes of expression: (1) undetectable, (2) faint, (3) moderate and (4) high. Expression of both proteins was ®rstly analysed in control normal lung (Tables 1 and 2 , Figure 1a ). p15 product was undetectable in four samples whereas it was faintly (two cases) or moderatly (two cases) expressed in the four other cases. p15.5 protein was detected in all samples. Expression was moderate in one case. Low expression was found in the seven other cases but heterogeneous levels were observed between the samples within this class of expression. Overall, p15 and p15.5 expression levels vary in the same way in each sample and a direct correlation between p15 and p15.5 expression was observed in the control normal lung (P50.04). Tumour-associated normal lung was available for 12 of the 20 lung carcinoma included in this study (Tables  1 and 2 , Figure 1b ). p15 product was undetectable in 6/ 12 (50%) samples and expressed at a low (four cases) or a moderate (two cases) level in the six other cases (50%). Expression of p15.5 was undetectable in three of these 12 (25%) cases. In the nine other samples, the level of p15.5 expression was indierently low, moderate or high (three cases each) and was globally higher than in the control normal lung samples expressing p15.5 (P50.02). Moreover, in contrast with control normal lung, p15 and p15.5 expressions were not correlated in tumour-associated normal samples.
We then analysed the expression of both proteins in NE lung tumours (Tables 1 and 2, Figure 1c ). p15 and p15.5 were undetectable in 9/20 (45%) and 4/20 (20%) tumour samples respectively. In others, the level of expression of each isoform was highly variable, from low to high. p15 or p15.5 expression level was not signi®cantly dierent between low and high grade NE lung tumours but p15.5 expression was more variable in low than in high grade tumours (P50.02). As in associated normal lung, p15 and p15.5 expressions were not correlated to each other in tumour samples. When compared to associated normal lung, loss of p15 expression was found in 1/12 (8%) tumours whereas increased expression was detected in 3/12 (25%) tumours (Table 2 ). In the eight other cases (67%) expression was apparently the same. Same analysis was performed with p15.5 product. We observed that its expression was lost in 1/12 (8%) cases, increased in 5/ 12 (42%) cases, decreased in 4/12 (33%) cases and unchanged in 2/12 (17%) cases. Thus, expression of p15 and p15.5 proteins in tumours was distinct from those observed in associated normal lung in 33% (4/12) and 83% (10/12) of the cases respectively (Figure 2 ). LCNEC, Large Cell Neuroendocrine Lung Carcinoma, SCLC, Small Cell Lung Carcinoma. Immunoblots of p15 and p15.5 were analysed by densitometry and the resulting data were grouped as described in Materials and methods section in four classes of expression: (1) undetectable d=0, (2) faint 05d540333; (3) moderate 403335d580667 and (4) high 806775d5121000, d, densitometric value 
NL, normal lung; ANL, normal lung associated to low grade NE lung tumours; ANL*, normal lung associated to high grade NE lung tumours;
LG, low grade tumours; HG, high grade tumours; ND, not down. P15 and p15.5 expression were studied by Western blotting. p16
INK4a expression and methylation status were analysed using immunohistochemistry and PCR based-assay respectively, as previously described (Gazzeri et al., 1998a) . p14 ARF protein status was analysed using immunohistochemistry as previously described (Gazzeri et al., 1998b) Overall, p15 expression tended to be more heterogeneous in tumours than in associated normal lung (P50.055), specially in high grade NE tumours (P50.05). The level of p15.5 was signi®cantly higher in tumours than in control normal lung (P50.02), specially in low grade tumours (P50.01). Furthermore, p15.5 expression was globally more variable in tumours than in control normal lung (P50.01).
Taken together, these data indicate that p15.5 expression levels and variability increased progressively during lung tumorigenic process, from control normal lung to tumour associated normal lung and to tumour, whereas changes in p15 expression mostly occurred in tumours. (Figure 3) . A methylation speci®c PCR (MSP) was used to study two others CpG islands located in an upstream region around the transcription start (Figure 3 ). Analysis at these sites allowed correlation studies with both p15 and p15.5 expression. Methylation could be studied in the eight control normal lung of the control group, the 20 tumour samples and ®ve associated normal lung.
Methylation proximal to the translation start (PCR based-assay) (Table 2, Figure 4a) Methylation within the sensitive-endonucleases sites located proximal to the translation start (HpaII, BssHII, HhaI and SacII) was never detected in all control normal lung. In contrast, methylation of the upstream EagI site was observed in seven of these eight control normal cases (Figure 4a ).
Of the 20 tumours analysed, one showed methylation with ThaI and EagI site (T13), three with Eag1 site only (T1, T4 and T16), one with ThaI only (T14) and one with SacII (T2) (Figure 4a) . Overall, the pattern consistent with methylation at Eag1 site was observed in 4/20 (20%) tumours whereas methylation at one of the other sites was found in 3/20 (15%) tumours. Associated normal lung was available for study in two of the six methylated tumours. The same pattern of methylation was detected in one case (EagI, T4). In the other case, methylation was not found at any site. Two tumour-associated normal lung, displayed methylation at the EagI site, whereas the corresponding tumours did not. Raji and HL60 cell lines were used as positive and negative controls respectively in MSP analysis. As previously described (Herman et al., 1996b) , DNA from Raji cell line produced a strong PCR product with methylated primers and a weaker band with unmethylated primers (Figure 4b ). In contrast, HL60 displayed a PCR product only with unmethylated primers. As shown by ampli®cation with the methylated set of primers, pattern consistent with p15
INK4b methylation was observed in all tumour lung samples analysed and in nearly all (19/20) normal samples (control or associated with tumour cases) included in this study (Figure 4b ). In all cases, ampli®cation with the unmethylated set of primers gave a PCR product, re¯ecting persistence of unmethylated alleles. Sequencing was performed in seven methylated tumour samples, three methylated associated normal lung from cancer patients and in the control normal sample in which methylation was not detected using MSP. In all cases where methylation was detected by MSP analysis, it was con®rmed by sequencing ( Figure  4c ). However, in all cases, methylation was only detected by using speci®c methylated primers in ampli®cation and sequencing steps indicating that the number of methylated alleles was probably low. Interestingly, multiple unconverted cytosines were also detected in the normal sample negative by MSP showing that methylation had occurred. Evidence of EagI methylation by PCR basedassay was con®rmed by MSP in 13/14 samples.
Relation between protein expression and methylation status of p15
INK4b gene
When compared to Western blot data, no clear correlation was observed between p15 INK4b methylation status (proximal to and/or upstream the translation start) and expression of p15 and/or p15.5 proteins (Table 2) . Thus, our data suggest that the variable expression of either p15 or p15.5 proteins could not be simply explained by a speci®c methylation status of p15
INK4b gene promoter, at least at the studied sites and with the techniques used, but might occur at a post-transcriptional level.
P16
INK4a expression and methylation status in NE lung tumours and correlation with p15
INK4b status (Tables 2 and 3, Figure 5) In a previous study, we concurrently performed p16
INK4a immunostaining and PCR based assay to analyse p16
INK4a expression and methylation status in non small cell lung cancer (Gazzeri et al., 1998a Figure 5a ). Patterns consistent with p16
INK4a methylation were observed in four of these ®ve lung tumours (SacII for LG4, HG2 and HG3 and SacII and CfoI for HG12) and were never found in the tumours with positive p16 INK4a immunostaining (Figure 5b ). Normal lung tissue was available in one of the ®ve tumours displaying p16 INK4a methylation (ANL4) and DNA hypermethylation was not observed, in agreement with our previous analysis (Gazzeri et al., 1998a) .
We found no inverse nor direct correlation linking p15.5 and p16
INK4a expression (Table 3) . Although p15 and p16
INK4a proteins were either concurrently coexpressed or co-undetectable in 14 of 20 (70%) NE lung tumours, a signi®cant correlation was not observed. No correlation was found between the methylation status of both genes. However, although neither p15
INK4b nor p16 INK4a methylation were detected in 11/20 (55%) tumours, we noticed that methylation of either gene was more frequent (8/20, 40%) than that of both genes (1/20, 5%).
Comparison of p15
INK4b and p14 ARF expression in NE lung carcinoma (Tables 2 and 4) Results of p14 ARF immunostaining performed previously on the same series of NE lung tumours used here (Gazzeri et al., 1998b) , have been presented again (Tables 2 and 4 ) to allow comparison between the expression of p14 ARF and p15 or p15.5 proteins. There was no inverse nor direct correlation linking p14 ARF and p15 or p15.5 expression (Table 4) .
Discussion
The role of p15
INK4b in human lung carcinogenesis has been poorly investigated and its expression (mRNA or protein) has never been studied. In this study, we demonstrate for the ®rst time that expression of p15 and p15.5 products is highly heterogeneous in low and high grade NE tumours without any apparent correlation with the methylation status of p15
INK4b
. INK4a gene by PCR based-assay in NE lung tumours. Study of tumour HG12 is illustrated as an example. DNA was digested with MspI (M), SmaI (S), HpaII (H), SacII (s) or CfoI (C). Digested or undigested (U) DNAs were then ampli®ed with speci®c primers as previously described (Gazzeri et al., 1998a) . Methylation with SacII and CfoI was detected in this case Moreover, we show that p15.5 expression is strongly variable in normal lung/tumour pairs suggesting a potential role of p15.5 during the carcinogenesis of NE lung tumours. Expression of both p15 and p15.5 products has never been investigated in normal tissues. A highly surprising ®nding in this study was the variable pattern of p15 and p15.5 expression between patients, both in control and tumour-associated normal cells. Methylation of p15
INK4b gene has been previously reported in lymphocytes from healthy patients (Aggerholm et al., 1999) . As a same minor population of lymphoid cells was detected in all the normal lung samples included in this study (data not shown), we ruled out that p15 and p15.5 heterogeneous expression could not be accounted for by variations in lymphocytes content. We investigated the possibility to detect p15
INK4b expression in situ by using immunohistochemistry. However, we could not assess p15
INK4b expression since available antibodies disclosed strong and dominant contaminating bands in Western blot analysis, rendering immunoreactivity questionable. A clear expression of p15 transcript has been reported in many normal tissue types including lung (Gonzalez-Zuluetta et al., 1995; Cameron et al., 1999; Stone et al., 1995) whereas low or undetectable levels of expression were observed in some others . Thus, expression of p15 mRNA appears variable according to tissue types and it is actually unknown if these dierences re¯ect a tissuespeci®c requirement for the p15
INK4b proteins. Since p15 and p15.5 are synthesized from the same transcript (Fuxe et al., 2000) , it is unlikely that their dierential expression in normal lung might be related to variation in the level of p15 mRNA synthesis. In contrast, their variations might be the result of translational or posttranslational regulations. Consistent with this, Gray-Gablin et al. (1997) have reported that some breast normal epithelial cells express very high levels of p15 protein despite low levels of p15
INK4b mRNA. We showed that p15 product is often undetectable, independently of tumour feature, whereas expression of p15.5 is more frequent and higher than that of p15 in tumours and associated normal lung. These data indicate that regulation of p15 and p15.5 is not always coordinated arguing in favour of functional dierences. Furthermore, they suggest that carcinogenesis is implicated in these variations. Accordingly, p15 and p15.5 expressions were highly correlated in normal lung whereas they were not in tumours and associated normal lung. Furthermore, a distinct expression of both proteins was observed between NE lung tumours and associated normal lung. P15.5 appears as the major target of this deregulation, and its variation in the associated normal lung taken in the vicinity of the tumours might re¯ect changes in the cancerization ®eld. Surprisingly, either up-or downregulation of protein expression with regard to associated normal lung was observed. We cannot actually explain the biological consequences of such variations. However, it is interesting to note that the same heterogeneous pattern of expression was also detected when the global expression of p15and/or progression of these malignancies. In the present study, we showed evidence of a selective deregulation of p15
INK4b in some NE lung tumours suggesting its potential implication in bronchial carcinogenesis. Furthermore, we found p15
INK4b status to be independent of that of p16
INK4a and p14 ARF genes indicating that regulation of these three genes is distinct. Altogether these data add further support for a distinct functional role for p15 INK4b . We found that p15.5 expression was more variable in low grade than in high grade NE lung tumours suggesting a selective implication of p15.5 deregulation in these benign carcinoma. Although they were presented historically as a spectrum of NE tumours with increased malignancy from typical carcinoid to SCLC, low and high grade NE lung tumours are presently considered as two independent entities with dierent histogenesis, carcinoids deriving from a NE stem cell whereas SCLC would share more similarities in mRNA pro®le with an epithelial bronchial cell (Anbazhagan et al., 1999) . Because they harbour distinct genetic abnormalities as regard to RB deregulation pathway (Yuan et al., 1999; Dosaka-Akita et al., 2000) , the selective deregulation of p15.5 might re¯ect the dierent pathologies and outcome of these two classes of tumours. In conclusion, our data give a clear entity to p15
INK4b gene of which deregulation processes in lung tumorigenesis remain to be elucided.
Materials and methods
Tissue samples and cell lines
Tissue samples were taken at surgical resection or at mediastinoscopy. They were immediately frozen and kept at 7808C until use. They consisted of eight control normal lung from patients with no cancer history, mostly presenting with bullous emphysema, 20 NE lung tumours and 12 associated normal lung taken at distance from tumour on lobar resection or in another lobe on pneumonectomy. Tumour samples were three typical carcinoids, two atypical carcinoids, 11 large cell neuroendocrine carcinoma and four small cell lung carcinoma according to the 1999 WHO international classi®cation of lung cancer (Travis et al., 1999) . Typical and atypical carcinoids were considered as low grade NE lung tumours whereas large cell neuroendocrine carcinoma and small cell lung cancer were considered as high grade NE lung carcinoma.
Western blot analysis of p15/p15.5
Cells and tumour samples were lysed in 100 mM tris pH=8, 150 mM NaCl, 5 mM EDTA, 0.5% SDS, 0.5% NP40, 0.5% Na deoxycholate, 0.1% aprotinine, 2 mg/ml leupeptine, 2 mg/ml pepstatine and 1 mM PMSF, then incubated 30 min on ice and centrifugated for 30 min at 12 000 r.p.m. at 48C. Equal amounts of protein (40 mg) were loaded onto a 15% SDS ± PAGE gel and transferred to PVDF membranes (Amersham). The membrane was blocked for 30 min in 5% dry milk and probed overnight at 48C with the p15 polyclonal antibody (C20, Santa Cruz) at 1/5000 dilution. Detection was performed with enhanced chemiluminescence detection system (ECL, Amersham). HL60 and BT20 cell lines were used as positive and negative controls respectively. Because the intensity of the signal of each isoform was highly variable, immunoblots were analysed by densitometry using NIH 1.6 software. In each blot, HL60 was used as an internal control in order to allow comparison between the blots. Loading was normalized using anti-actin probing (polyclonal anti-actin (20 ± 33) from Sigma-Aldrich) and further quanti®cation using NIH 1.6 software. For each protein, the resulting densitometric values were grouped into four classes of intensity and dierential expression was attributed to each of these groups as follows: x=0 class (1) undetectable expression, 05x540333 class (2) faint expression, 403335x580667 class (3) moderate expression, 806775x5121000 class (4) high expression.
Immunohistochemistry (IHC)
Expression of p16
INK4a was studied on frozen sections using the mouse monoclonal antibody p16
INK4a (Pharmingen, CA, USA) at 1/100 dilution and the rabbit polyclonal antibody p16 C-20 (Santa Cruz, CA, USA) at 1/750 dilution as previously described (Gazzeri et al., 1998a) . Expression of p14 ARF was studied as previously described (Gazzeri et al., 1998b ) using a rabbit polyclonal antibody (Della Valle et al., 1997) at 1/2000 dilution, kindly provided by JC Larsen, and a goat polyclonal antibody to p14 ARF (C-18) (Santa Cruz, CA, USA) at 1/300 dilution.
PCR based-assay
Genomic DNA was extracted from fresh frozen tissues using standard proteinase K treatment and phenol/chloroform/ isoamylalcohol extraction. One mg of genomic DNA was digested overnight with 2.5 units of methylation-sensitive (EagI, HpaII, SacII, HhaI, BsshII and ThaI for p15 INK4b analysis and HpaII, cfoI, SacII and SmaI for p16 INK4a analysis) and methylation-insensitive (MspI) enzymes. It should be noticed that EagI restriction site overlapped with the sequence of the downstream methylated primer used in MSP analysis. Digested DNA (50 ng) was then ampli®ed by PCR using primers¯anking the restriction sites. For EagI digests, the primers were sense 5'-TTCCCAGAAGCAATC-CAG3' and antisense 5'-TAGGAGACCTGGGCTCAG-3'. For BssHII digests, the primers were sense 5'-AACGGTG-GATTATCCGGGCCGCT-3' and antisense 5'-AAATCTA-CATCGGCGATCTAGGTT-3'. For all others restriction digests of p15
INK4b analysis, the primers were sense 5'-AGCTGAGCCCAGGTCTCCTA-3' and antisense 5'-CGCCTCCCGAAACGGTTGAC-3'. For p16 INK4a analysis, the primers used were as described previously (Gazzeri et al., 1998a) . Labelling of the PCR products was performed directly using [a-33 P]dATP during PCR. Five ml of PCR products were loaded onto a 5% polyacrylamide gel. Undigested and MspI-digested DNAs were used as controls and were included for every site examined. To rule out the possibility of incomplete digestion, all samples were digested twice with each of the enzymes in independent experiments. PCR ampli®cations from each of the duplicate digests were repeated at least twice to ensure reproducibility of the results.
Bisulfite modification of DNA and methylation specific PCR Genomic DNA (4 mg) was digested with EcoRI at 378C overnight in a total volume of 20 ml. Denaturation was performed during 15 min at 758C by addition of 2 ml of NaOH 3 M. Modi®cation was carried out using 250 ml of NaHSO3 4.8 M and 14 ml of 10 mM hydroquinone and incubation was performed under mineral oil at 558C for 4 h in the dark. Modi®ed DNA was then puri®ed using the Clean up system kit (Promega) and eluted into 50 ml H 2 O. Desulfonation was achieved by addition of 25 ml NaOH 1 M and incubation at room temperature for 3 min. After ethanol precipitation, modi®ed DNAs were resuspended in 50 ml H 2 O. MSP was performed using primers previously designed to discriminate heavily methylated CpG islands from unmethylated alleles (Herman et al., 1996b) . PCR conditions used to amplify modi®ed unmethylated DNA with the primers p15-U sense and antisense were: one cycle at 958C for 5 min; 35 cycles at 958C (30 s), 608C (90 s), and 728C (30 s) each, and a ®nal extension at 728C for 5 min. Ampli®cation of modi®ed p15
INK4b methylated DNA was performed using nested PCR. First PCR was carried out using 1 ml of modi®ed DNA and the primers sense 5'-TTTTTTGTAGGTTGGTTTTT-TATTTTG-3' and anti-sense 5'-AAACTAAACTCAACTT-CATTACCCTC-3' in a ®nal volume of 10 ml. PCR was performed for 25 cycles using the following conditions: 958C for 30 s, 558C for 30 s and 728C for 30 s. Then, 0.1 ml of ®rst PCR was ampli®ed in a total volume of 10 ml using the primers p15-M sense and antisense (Herman et al., 1996b) . PCR was carried out for 25 cycles at 958C for 30 s, 608C for 30 s and 728C for 30 s each. PCR products were loaded onto 2% agarose gels and stained with ethidium bromide. Each sample was modi®ed twice in independent experiments and PCR ampli®cations from each of the duplicate were repeated at least twice to ensure reproducibility of the results. Raji and HL60 cell lines were used as positive and negative controls respectively in MSP analysis.
Sequencing
Modi®ed DNA was ampli®ed using the primers sense 5'-TTTTTTGTAGGTTGGTTTTTTATTTTG-3' and antisense 5'-AAACTAAACTCAACTTCATTACCCTC-3'. PCR was performed for 40 cycles at 958C for 30 s; 568C for 30 s and 728C for 30 s each. PCR products were puri®ed using Wizard PCR prep DNA puri®cation system' (promega) and sequenced with the 5'-CGTACAATAACCGAAC-GACCGA-3' primer using the USB sequencing Kit (Amersham).
Statistical analyses
Statistical analyses were performed using the Fisher's exact test for dierences between groups, the t-test between means and the Spearman test for correlation.
